GENE ONLINE|News &
Opinion
Blog

2021-06-21| Trials & Approvals

FDA Greenlights Blueprint Medicines’ Ayvakit for Rare Disease Treatment

by Rajaneesh K. Gopinath
Share To

Blueprint Medicines had a great start to 2020, bagging its very first FDA approval. Its kinase inhibitor, Ayvakit (avapritinib), won the agency’s nod for treating adults with an unresectable or metastatic gastrointestinal stromal tumor harboring a PDGFRA Exon 18 mutation. Since then, the Cambridge, MA-based company has had a great run with the drug regulator, bagging two more authorizations. Last week, it notched its fourth approval, a second for Ayvakit.

On June 16th, the FDA greenlit Ayvakit for treating adults with advanced systemic mastocytosis (Advanced SM), including aggressive SM (ASM), SM with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).

“Today’s approval of Ayvakit for advanced systemic mastocytosis – the fourth FDA approval across our portfolio in 18 months – culminates nearly a decade of hard work, from our scientists in the laboratory and clinical team conducting trials, to our commercial organization who will now bring Ayvakit to patients,” said Jeff Albers, CEO of Blueprint Medicines.

 

Advanced SM – A Rare Disease

Advanced SM is a rare disease driven by the KIT D816V mutation. Most victims are affected by the non-advanced form of SM, which negatively impacts their quality of life. However, patients suffering from advanced SM experience organ damage due to mast cell infiltration and poor survival. Before Ayvakit, the only therapeutic options available were those that offered symptomatic relief.

“Advanced systemic mastocytosis is a debilitating disease characterized by extensive damage in multiple organ systems due to mast cell infiltration, and new treatment options are urgently needed to address these life-threatening complications,” said Dr. Daniel DeAngelo, from the Dana-Farber Cancer Institute.

Ayvakit is the first FDA-approved therapy for this condition. The full approval is based on results from the Phase 1 EXPLORER trial and Phase 2 PATHFINDER trial. Results showed that the drug demonstrated durable clinical efficacy in advanced SM patients across disease subtypes irrespective of their prior treatment status.

“Avapritinib will clearly establish a new standard of care for patients with advanced systemic mastocytosis. The FDA approval was based on data showing robust and durable responses, including complete remissions and a favorable safety profile. For advanced SM patients, the approval of avapritinib shifts the treatment paradigm toward precision therapy that targets the primary driver of mastocytosis.” Dr. DeAngelo added.

Earlier this year, Blueprint announced that Ayvakit raked in $6 million in net product revenue during the fourth quarter of 2020. In March, the drug had received validation from the EMA for the type II variation marketing authorization application for advanced SM. With no competitor drugs for this indication and a likely EMA approval looming, Blueprint would be anticipating a profitable year in global Ayvakit sales.

Related Article: Biogen’s Controversial Alzheimer’s Drug Wins Historic FDA Approval

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
FDA Boxed Warning for CAR-T therapy, Affecting Bristol-Myers Squibb, Novartis, Janssen, Gilead Sciences
2024-01-24
FDA’s Boxed Warning Highlights Low Calcium Dangers with Prolia
2024-01-22
Groundbreaking CRISPR/Cas9-based Genome Editing Therapy Secured the Second FDA Approval
2024-01-18
LATEST
Why NVIDIA’s CEO Huang Said AI Fostering Life Science:Highlighting GPU’s Applications in Biotech
2024-02-23
Revolutionary AI-Powered Respiratory Monitor Maker Gets Financial Boost with Latest Funding
2024-02-21
Researchers Predict Drug Interactions with Machine Learning to Enhance Patient Safety
2024-02-21
USC-Led Study Reveals Benefits of Fasting-Mimicking Diet in Reducing Disease Risk and Slowing Aging
2024-02-21
Astonishing brain tumour research wins the BIAL Award in Biomedicine 2023 worth 300,000 Euro
2024-02-21
Targeted Cancer Therapy Breakthrough: Degrader-Antibody Conjugates (DACs) Advance to Clinical Trials
2024-02-19
Degrader-Antibody Conjugates (DACs): Targeted Degradation for Therapeutics
2024-02-19
EVENT
Scroll to Top